New York – August 15, 2019 – Having been one of the world’s leading chemical vendors for nearly two decades, this month BOC Sciences announces to promote its antibody drug conjugate service for scientists engaged with drug R&D both academically and industrially. After this move, researchers can have easy access to this CRO service with more favorable price but with no compromise to efficiency, expertise and quality.
Antibody drug conjugates (or ADCs), as its name suggests, are monoclonal antibodies (mAbs) conjugated to biologically active drugs by ADC linkers with bonds to combat invading microbes or malignant cells. With the prevalence of targeted therapy and precision medicine, ADCs are becoming an emerging class of anti-cancer treatment agents, and have received worldwide attention for their unparalleled benefits, especially in the treatment of certain solid tumors and lymphomas.
“Traditionally, chemotherapy has been the mainstay of cancer treatment; however, its efficacy is quite limited and various side effects come along with it, causing unnecessary death to those healthy cells inside our body,” commented Prof. Jones, a senior scientist from BOC Sciences. “ADCs, by linking antibody and biological drug together, now have both the selectivity of targeted treatment and the cytotoxic potency of chemotherapy drugs.”
In spite of the fact that a large scale of investigation concerning antibody drug conjugates has been carried out in the last few decades, not many extraordinary breakthroughs are made yet. The most commonly identified weaknesses that restrict the ADC effectiveness are: low drug potency of chemotherapy, unstableness of linkers and low selectivity of antigens. It is only recently that ADC’s true potentials were fully tapped, thanks to the significant advances in linker engineering, conjugation technologies and continuous development of highly potent cytotoxic drugs.
“In short, to design the most ideal ADC, we should focus on the following three aspects: target antigen, antibody selection, linkers and conjugation,” adds Prof. Jones. “First, we need to make sure that the target antigen we choose is highly expressed on tumor cells and has no expression on normal tissues; second, the linkers should be stable, otherwise, it will negatively influence the ADC’s pharmacokinetics, therapeutic index and efficacy.”
Currently, BOC Sciences’ integrated capabilities for ADCs design are listed as below; meanwhile, various ready-for-use ADC linkers and ADC Cytotoxin are also available.
• Synthesis and characterization of small molecule drugs;
• Conjugated antibodies, polymers, proteins and fluorophores;
• Biotin, ADC, Polymer–drug, Polymer-drug-target ligand conjugation;
• Drug substance characterization;
• Process development;
• Technology transfer;
• Analytical method development and validation.
For more information, please visit https://www.bocsci.com.
About BOC Sciences
BOC Sciences has been closely involved with drug discovery, chemistry and life science by supplying a comprehensive collection of chemicals to researchers, such as inhibitors, metabolites, impurities and natural compounds. Meanwhile, it also provides a wide range of services through all stages of drug R&D to support the pharmaceutical industry, like custom synthesis of chemicals, isotope labeling, formulation service, antibody drug conjugates, chiral synthesis and resolution.
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1631 619 7922
Address:45-16 Ramsey Road, Shirley
State: NY 11967
Country: United States